The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial
Abstract
Purpose: Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients. Methods: This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb ≤ 105 g/L, serum ferritin ≤ 450 pmol/L or ≤ 675 pmol/L with transferrin saturation ≤ 19%) receiving subcutaneously rHuEPO 40,000 U once weekly to: (1) no-iron; (2) oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI). Hb and quality of life (QOL) were measured at baseline and throughout. Results: All groups showed Hb (P < .0001) increases from baseline. Mean Hb increases for both IV iron groups were greater (P < .02) than for no-iron and oral iron groups. The percentage of patients with hematopoietic responses was higher (P < .01) in both IV iron groups (each case 68%) compared with no-iron (25%) and oral iron (36%) groups. IV iron groups showed increases in energy, activity, and overall QOL from baseline, compared with a decrease in energy and activity for no-iron group and no change in activity or overall QOL for oral iron group. Conclusion: rHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia. Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Progress in understanding the pathogenesis of the anemia of chronic disease [see comments]
Means, R. J., & Krantz, S. (1992) · Blood · doi:10.1182/blood.v80.7.1639.1639 · Cited by 681
Decreased Erythropoietin Response in Patients with the Anemia of Cancer
Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D., & Spivak, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222401 · Cited by 658
Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2875 · Cited by 595
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C. R. V., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 417
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.177 · Cited by 417
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Tolkien, Z., Stecher, L., Mander, A. P., Pereira, D. I. A., & Powell, J. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117383 · Cited by 833
Anemia and Patient Blood Management in Hip and Knee Surgery: A Systematic Review of the Literature
Spahn, D. R. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181e08e97 · Cited by 650
The Safety of Intravenous Iron Preparations
Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., & Gafter-Gvili, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.007 · Cited by 441
Detection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
Bokemeyer, C., Aapro, M. S., Courdi, A., Foubert, J., Link, H., Österborg, A., Repetto, L., & Soubeyran, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.014 · Cited by 403
Acheson, A. G., Brookes, M. J., & Spahn, D. R. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31825b35d5 · Cited by 402
Litton, E., Xiao, J., & Ho, K. M. (2013) · BMJ · doi:10.1136/bmj.f4822 · Cited by 394
Erythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
Iron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361
Guidelines on the diagnosis and treatment of iron deficiency across indications: A systematic review
Peyrin-Biroulet, L., Williet, N., & Cacoub, P. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.103366 · Cited by 328
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3396 · Cited by 327
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
Auerbach, M., & Ballard, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.338 · Cited by 310
Self-citationManagement of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx758 · Cited by 288
Henry, D. H., Dahl, N. V., Auerbach, M., Tchekmedyian, S., & Laufman, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-231 · Cited by 264
Self-citationLudwig, H., Müldür, E., Endler, G., & Hübl, W. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt118 · Cited by 259
Diagnosis and Treatment of Cancer-Related Anemia
Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23628 · Cited by 242
High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030255 · Cited by 56
Self-citation
Metadata
- Authors
- Auerbach, M., Ballard, H., Trout, J. R., McIlwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L., & Rana, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-04-01
- Volume
- 22
- Issue
- 7
- Pages
- 1301-1307
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147453280
- Cited by
- 414
- References
- 23
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.